TRDX & Genesis Biopharma Introduce Potential Cure for Diabetic Neuropathy

   SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) recently executed a Letter of Intent with Genesis Biopharma, Inc. ("Genesis") to advance development of a cure to one of the major problems facing people suffering from diabetes -- NEUROPATHY.

Diabetic neuropathy is one of the most severe side effects of diabetes and is caused by the deterioration of nerve fibres in the leg and arm. Neuropathy is manifested by slight numbness or tingling pain in the toes and fingers initially and then migrating to the entire foot, legs, hands, and arms. The risk of getting nerve damage increases with age and the longer an individual has diabetes.

1.  According to the World Health Organization there are approximately 220
    million people worldwide who have diabetes
    (http://www.who.int/mediacentre/factsheets/fs312/en/). In the U.S.,
    according to the 2007 National Diabetes Fact Sheet, a total of 23.6
    million had diabetes of which 17.9 million were already diagnosed and
    the rest, 24%, were undiagnosed
    (http://www.diabetes.org/diabetes-basics/diabetes-statistics/). If you
    add the undiagnosed cases to the 220 million reported by the World
    Health Organization the total number could exceed 270 million worldwide.


2.  Diabetes is the leading known cause of neuropathy in developed
    countries. It is estimated that the prevalence of neuropathy in diabetes
    patients is approximately 20% (See Epidemiology section in
    http://en.wikipedia.org/wiki/Diabetic_neuropathy). That results in more
    than 50 million estimated cases worldwide and about 5 million estimated
    cases in the U.S. of diabetic neuropathy.


3.  Diabetic neuropathy can cause nerve damage in the feet that leads to
    decrease or loss of sensation. As a result, a blister or a cut can go
    unnoticed. Any infection that might ensue can result in tissue death
    (gangrene) and in some cases severe damage can lead to amputation of
    toe, foot or even leg. Each year about 80,000 - 84,000 amputations are
    performed in the U.S. alone (See Diabetes-Related Amputation Statistics:
    http://www.isletsofhope.com/diabetes/complications/amputation_1.html#diabetes).
    How many of these amputations could have been avoided had a solution
    been made available?

Mr. Leo Stella, CEO of Genesis, stated: "Until now, there is absolutely no mechanism based treatment that can reverse neuropathy associated with diabetes. Drugs exist that have a temporary effect on the pain, but these drugs can not cure the cause. As stated above, there are more than 50 Million people worldwide and about 5 million in the U.S. who suffer from nerve damage of some kind that affects their ability to sleep, walk, drive a vehicle, and do just about any task that requires movement without pain. The goal of Genesis Biopharma is to develop a drug that will cure this terrible condition."

Genesis' work includes conducting pre-clinical and clinical trials to develop novel pharmaceutical therapies for the treatment of painful diabetic neuropathy.

Recently, Pre-clinical development has been completed for the treatment of painful diabetic neuropathy [pharmacology, toxicology, ADME (Absorption, Distribution, Metabolism and Excretion) in two species (rodent and non-rodent: rat and dog)] and clinical development (first formulation, part of the stress and stability studies of the drug substance and drug product). In addition, a CTA has been successfully obtained from the Therapeutic Product Directorate (TPD) of Health Canada to initiate Phase I-a clinical trial.

Dr. Jan Stahl, CEO of TRDX, commented: "Genesis has gotten to a key stage of development; we look forward to financing and finalizing our transaction with Genesis and working hard to make this potential cure a reality."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell of every living thing on Earth. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called "amide bonds").

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

Contact: SciMeDent Health Corp. f/k/a Trend Exploration, Inc. [e-mail] 1-866-383-1374